| Nov 11 |
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
|
| Nov 11 |
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
|
| Nov 11 |
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
|
| Nov 11 |
AbbVie Stock Slides on Schizophrenia Drug Study Failure
|
| Nov 11 |
AbbVie declines after missing main goal in schizophrenia treatment trials
|
| Nov 11 |
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
|
| Nov 11 |
AbbVie shares slip after schizophrenia drug trial misses primary endpoint
|
| Nov 11 |
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
|
| Nov 11 |
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
|
| Nov 10 |
3 Spectacular High-Yield Dividend Stocks to Buy in November
|
